SEER INC

SEERNASDAQ

🏆 #3328 by market capUS Equity

$964.64▲ $1.54 (+0.16%)

Simulated price

1h—

24h▲ 0.2%

7d—

14d—

30d—

1y—

🏦Market Cap

$119M

Small Cap

📈Revenue Growth (YoY)

-27.4%

Declining

📊Gross Margin

47.5%

Healthy

💵FCF Margin

—

⚖️P/S Ratio

10.7x

Elevated

Otter Score

Weak

No chart data available for SEER.

Trading Snapshot

Day Range: $951.90 – $970.01
52-Week Range: $1.55 – $2.41
Volume: $1.78B
Avg Volume: $2.19B
Shares Outstanding: 55.0M
Next Earnings: Oct 19, 2026

Fundamentals Snapshot

Annual Revenue: $16M
Last Q Revenue: $3M
P/E Ratio: —
P/S Ratio: 10.7x
EPS (TTM): $-1.24
Dividend Yield: —

Why Investors Own SEER

✓High-growth profile — revenue up +35.0% YoY with expanding US Equity exposure.
✓Healthy economics — 49% gross margin and 23% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$16M▲ +28.7% YoY

Gross Margin (TTM)

49.2%▲ +2.9% YoY

Operating Income (TTM)

$3M▲ +28.7% YoY

Free Cash Flow (TTM)

$4M▲ +28.7% YoY

About SEER INC

Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.

🦦